Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00968825 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Lateral Canthal Lines
Crow's Feet
Facial Wrinkles

Interventions

DRUG: Botulinum Toxin Type A
DRUG: Placebo

Sponsor

Revance Therapeutics, Inc.